Contact
Please use this form to send email to PR contact of this press release:
Data from 223-Patient Phase 2b Clinical Trial of Galera Therapeutics’ GC4419 Presented at 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
TO: